The Effect of Pioglitazone on Left Ventricular Mass & Function, Plasma Levels of Inflammatory, Endothelial & Thrombotic Biomarkers & Psychiatric indicators in non-Diabetic Patients with Metabolic Syndrome.

Trial Profile

The Effect of Pioglitazone on Left Ventricular Mass & Function, Plasma Levels of Inflammatory, Endothelial & Thrombotic Biomarkers & Psychiatric indicators in non-Diabetic Patients with Metabolic Syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Ischaemic heart disorders; Metabolic syndrome
  • Focus Pharmacodynamics
  • Acronyms EPICAMP
  • Sponsors Osvah Pharmaceutical Company
  • Most Recent Events

    • 09 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 27 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top